CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Phase 3

Terminated

Conditions: Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis

Interventions: Drug: FEDRATINIB

First Posted Date: 2018-11-28

Last Posted Date: 2024-12-12

Lead Sponsor: Celgene

Target Recruit Count: 38

Registration Number: NCT03755518

Locations: 🇺🇸
Local Institution - 123, Baltimore, Maryland, United States
🇨🇦
Local Institution - 200, Toronto, Ontario, Canada
🇺🇸
Local Institution - 112, Chicago, Illinois, United States

and more 32 locations

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Tislelizumab
Drug: Concurrent chemoradiotherapy (cCRT)
Other: Placebo

First Posted Date: 2018-11-19

Last Posted Date: 2020-07-15

Lead Sponsor: Celgene

Target Recruit Count: 1

Registration Number: NCT03745222

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸
Dayton Physicians, LLC, Kettering, Ohio, United States

and more 160 locations

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Phase 1

Terminated

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin

Interventions: Drug: JCAR017
Drug: Lymphodepleting
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-11-16

Last Posted Date: 2024-08-15

Lead Sponsor: Celgene

Target Recruit Count: 21

Registration Number: NCT03743246

Locations: 🇺🇸
Local Institution - 167, Redwood City, California, United States
🇺🇸
Local Institution - 161, Seattle, Washington, United States
🇺🇸
Local Institution - 165, Houston, Texas, United States

and more 16 locations

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: CC-90001

First Posted Date: 2018-11-15

Last Posted Date: 2020-07-27

Lead Sponsor: Celgene

Target Recruit Count: 40

Registration Number: NCT03742882

Locations: 🇺🇸
Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States

and more 1 locations

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Completed

Conditions: Lymphoma, T-Cell, Peripheral

Interventions: Drug: Istodax

First Posted Date: 2018-11-15

Last Posted Date: 2023-12-06

Lead Sponsor: Celgene

Target Recruit Count: 150

Registration Number: NCT03742921

Locations: 🇯🇵
Nihon Seimei Hospital, Osaka, Japan

Expanded Access for ACE-011

Conditions: Myelodysplastic Syndrome

First Posted Date: 2018-10-30

Last Posted Date: 2020-07-17

Lead Sponsor: Celgene

Registration Number: NCT03724227

Locations: 🇺🇸
Celgene, Summit, New Jersey, United States

Expanded Access for CC-2001

Conditions: Dermatologic
Other

First Posted Date: 2018-10-29

Last Posted Date: 2018-12-20

Lead Sponsor: Celgene

Registration Number: NCT03723083

Locations: 🇺🇸
Celgene, Summit, New Jersey, United States

Expanded Access for AG-221

Conditions: Acute Myeloid Leukemia

First Posted Date: 2018-10-29

Last Posted Date: 2019-10-24

Lead Sponsor: Celgene

Registration Number: NCT03723057

Locations: 🇺🇸
Celgene, Summit, New Jersey, United States

Expanded Access for CC-4047

Conditions: Multiple Myeloma

First Posted Date: 2018-10-29

Last Posted Date: 2018-12-20

Lead Sponsor: Celgene

Registration Number: NCT03723096

Locations: 🇺🇸
Celgene, Summit, New Jersey, United States

Expanded Access for CC-486

Conditions: Acute Myelogenous Leukemia (AML)

First Posted Date: 2018-10-29

Last Posted Date: 2020-09-18

Lead Sponsor: Celgene

Registration Number: NCT03723135

Locations: 🇺🇸
Celgene, Summit, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy